Session » Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 13

Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE

9:00AM-11:00AM: Abstract Number: 8

Bay 11-7085 Induces Glucocorticoid Receptor Activation and Autophagy to Initiate Human Synovial Fibroblast Cell Death

9:00AM-11:00AM: Abstract Number: 10

CD13/Aminopeptidase N Contributes to Angiogenesis and Monocyte Chemotaxis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 3

Cytokine Production Patterns in Osteoporosis Suggest a Pro-Inflammatory Bias

9:00AM-11:00AM: Abstract Number: 12

Delta-like 1 Enhances the Production of Pro-Inflammatory Mediators By Fibroblast-like Synoviocytes

9:00AM-11:00AM: Abstract Number: 17

Disentangling the Role of Hypoxia-Inducible Factor 1 and 2 in the Adaption Process of Human Microvascular Endothelial Cells to Pathophysiological Hypoxia

9:00AM-11:00AM: Abstract Number: 18

Epigallocatechin-3-Gallate (EGCG) Facilitates TAK1 Nuclear Translocation and Its Interaction with p300 to Inhibit Histone Acetylation in Human RA Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 22

Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis

9:00AM-11:00AM: Abstract Number: 7

Influence of TNF on Anti-Inflammatory Tyrosine-Hydroxylase-Positive Synovial Cells in Rheumatoid Arthritis and Osteoarthritis

9:00AM-11:00AM: Abstract Number: 23

Microvesicle-Associated Hsa-Mir-223-3p Is Elevated in Rheumatoid Synovial Fluid Compared with Osteoarthritis Synovial Fluid

9:00AM-11:00AM: Abstract Number: 19

Pentagalloyl Glucose (PGG) Exhibits Anti-Rheumatic Activity in Human RA Synovial Fibroblasts and Rat Adjuvant-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 5

Prospective Study of the Effect of Treatment with Adalumumab in Angiogenesis in Moderate or Severe Psoriasis for a Period of 6 Months

9:00AM-11:00AM: Abstract Number: 21

Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue

9:00AM-11:00AM: Abstract Number: 16

Rantes/CCL5 Selectively Induces MMP-1 and MMP-13 Production in Rheumatoid Arthritis Synovial Fibroblasts Via PKC-Î´ and JNK Pathways

9:00AM-11:00AM: Abstract Number: 15

Regulation of Neutrophil Extravasation By Interleukin-8-Induced Intravascular Reactive Oxygen Species Production during the Inflammatory Response

9:00AM-11:00AM: Abstract Number: 20

Role of the Epigenetic Regulator EZH2 in Proinflammatory Macrophage Polarization and Signaling in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 9

Serum Visfatin Levels in Patients with Axial Spondyloarthitis and Early Rheumatoid Arthritis: Relation to Inflammation and Bone Changes

9:00AM-11:00AM: Abstract Number: 4

The Influence of Adipokines on the Interaction of Rheumatoid Arthritis Synovial Fibroblasts with Endothelial Cells

9:00AM-11:00AM: Abstract Number: 1

The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of B Cells at the Inflammatory Foci

9:00AM-11:00AM: Abstract Number: 2

The Neutrophil Protein S100A12 Has Stronger Associations with a Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 6

The Novel Role of Corticotropin-Releasing Hormone and Urocortin1 on Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 14

The SLE Susceptibility Gene Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 (NOD-like receptor family pyrin domain containing 3) Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].